[前列腺癌生物标志物以及利用前列腺产生的ace进行前列腺癌和良性前列腺增生诊断的潜力]

[Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].

作者信息

Kamalov A A, Samokhodskaya L M, Karpov V K, Okhobotov D A, Mamedov V N

机构信息

) Faculty of Fundamental Medicine of Lomonosov Moscow State University, Department of Urology and Andrology, Moscow, Russia.

) Medical Scientific and Educational Center of Lomonosov Moscow State University, Moscow, Russia.

出版信息

Urologiia. 2019 Jun(2):73-81.

PMID:31162906

Abstract

Prostate cancer (PCa) is the 4th most commonly diagnosed cancer in the male population and incidence of different stages is increasing every year. The efficiency of PCa treatment is strongly dependent on the its stage. Prostate Specific Antigen (PSA) is the most widely used and universal biomarker of PCa worldwide. Considering its limited predictive value, particularly in patients older than 50 with PSA level ranging from 4.5 to 10 ng/ml, there is a need to introduce new serum biomarkers of PCa. Current data on different PCa biomarkers are reviewed in the article as well as a role of angiotensin-converting enzyme (ACE) as a novel PCa biomarker.

摘要

前列腺癌（PCa）是男性群体中第四大最常被诊断出的癌症，且不同阶段的发病率逐年上升。PCa的治疗效果在很大程度上取决于其所处阶段。前列腺特异性抗原（PSA）是全球范围内使用最广泛且通用的PCa生物标志物。鉴于其预测价值有限，尤其是在50岁以上、PSA水平在4.5至10 ng/ml之间的患者中，有必要引入新的PCa血清生物标志物。本文综述了关于不同PCa生物标志物的当前数据，以及血管紧张素转换酶（ACE）作为一种新型PCa生物标志物的作用。